"Pre-operative antiplatelet therapy:Pre-procedural antiplatelet therapy is not routinely required for WEB treatment, with approximately 90% of patients undergoing treatment without antiplatelet premedication 6."
"Post-operative antiplatelet therapy:Following WEB treatment, antiplatelet therapy is individualised according to procedural and angiographic findings. Patients with complete intrasaccular device deployment often require no antiplatelet therapy or single antiplatelet therapy (SAPT) alone, whereas SAPT or dual antiplatelet therapy (DAPT) may be prescribed in the presence of device protrusion into the parent vessel, adjunctive stenting, or other thromboembolic risk factors. Despite substantial interinstitutional variability in antiplatelet practice, outcomes appear unaffected by the specific antiplatelet regimen used 6."
"Pre-operative antiplatelet therapy:Pre-procedural antiplatelet therapy is not routinely required for WEB treatment, with approximately 90% of patients undergoing treatment without antiplatelet premedication 6."
"Pre-operative antiplatelet therapy:Pre-procedural antiplatelet therapy is not routinely required for WEB treatment, with approximately 90% of patients undergoing treatment without antiplatelet premedication 6."
"Post-operative antiplatelet therapy:Following WEB treatment, antiplatelet therapy is individualised according to procedural and angiographic findings. Patients with complete intrasaccular device deployment often require no antiplatelet therapy or single antiplatelet therapy (SAPT) alone, whereas SAPT or dual antiplatelet therapy (DAPT) may be prescribed in the presence of device protrusion into the parent vessel, adjunctive stenting, or other thromboembolic risk factors. Despite substantial interinstitutional variability in antiplatelet practice, outcomes appear unaffected by the specific antiplatelet regimen used 6."
"Woven EndoBridge (WEB) Aneurysm Embolisation System"
"Artisse™ (formerly LUNA) Intrasaccular device"
"Medina Embolic Device (MED)"
"Contour Neurovascular System™: hybrid design of neck-bridging and endosaccular device that aims to close the aneurysm at its neck, without the need to cater to the entire aneurysm volume or shape, therefore expanding its indications"
"Saccular Endovascular Aneurysm Embolisation System Device (SEAL)"
"Trenza Embolisation Device"
"Saccular Endovascular Aneurysm Embolisation System Device (SEAL)"
"Among them, WEB is the most widely known and studied device. Large European multicentre trials (WEBCAST and WEBCAST 2) illustrated a very high success rate (complete occlusion or neck remnant at one-year follow-up) in 80% with no device-related mortality and only 1.8-2% morbidity 2,4."
"Among them, WEB is the most widely known and studied device. Large European multicentre trials (WEBCAST and WEBCAST 2) illustrated a very high success rate (complete occlusion or neck remnant at one-year follow-up) in 80% with no device-related mortality and only 1.8-2% morbidity 2,4."
"Antiplatelet Therapy"
"Pre-operative antiplatelet therapy:Pre-procedural antiplatelet therapy is not routinely required for WEB treatment, with approximately 90% of patients undergoing treatment without antiplatelet premedication 6."
"Post-operative antiplatelet therapy:Following WEB treatment, antiplatelet therapy is individualised according to procedural and angiographic findings. Patients with complete intrasaccular device deployment often require no antiplatelet therapy or single antiplatelet therapy (SAPT) alone, whereas SAPT or dual antiplatelet therapy (DAPT) may be prescribed in the presence of device protrusion into the parent vessel, adjunctive stenting, or other thromboembolic risk factors. Despite substantial interinstitutional variability in antiplatelet practice, outcomes appear unaffected by the specific antiplatelet regimen used 6."
Expected headings
"Antiplatelet Therapy"
"Follow-up imaging"